NCT06887049 Achieving Routine Intervention and Screening for Emotional Health
| NCT ID | NCT06887049 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Chicago |
| Condition | Type 2 Diabetes Mellitus (T2DM) |
| Study Type | INTERVENTIONAL |
| Enrollment | 880 participants |
| Start Date | 2026-03-10 |
| Primary Completion | 2027-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 880 participants in total. It began in 2026-03-10 with a primary completion date of 2027-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this project is to evaluate the effectiveness of diabetes distress screening and intervention on patients with type 2 diabetes mellitus (T2DM).
Eligibility Criteria
Inclusion Criteria: * Patient at a participating clinic * Type 2 diabetes * Adult (18 years or older) * A1C \> 8% * English- or Spanish-speaking Exclusion Criteria: * Pregnant
Contact & Investigator
Arshiya Baig, MD, MPH
PRINCIPAL INVESTIGATOR
University of Chicago
Frequently Asked Questions
Who can join the NCT06887049 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Type 2 Diabetes Mellitus (T2DM). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06887049 currently recruiting?
Yes, NCT06887049 is actively recruiting participants. Contact the research team at abigail.durgan@bsd.uchicago.edu for enrollment information.
Where is the NCT06887049 trial being conducted?
This trial is being conducted at Chicago, United States.
Who is sponsoring the NCT06887049 clinical trial?
NCT06887049 is sponsored by University of Chicago. The principal investigator is Arshiya Baig, MD, MPH at University of Chicago. The trial plans to enroll 880 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.